Special Issue

Metastatic Soft-Tissue Sarcomas

Message from the Guest Editors

Sarcoma treatment and research focusses on a cure: at present, 50-60% of patients will face a metastatic and/or progressive disease within 5 years after diagnosis. Surgical resection remains the mainstay of treatment with curative intent, where radiation is successfully added in a neoadiuvant setting, improving local control and perhaps improving the chances of survival. Chemotherapy in a neoadjuvant setting is only proven to be effective in a small subset of sarcoma patients. This changes in the palliative setting, where balancing quantity and quality of live becomes even more important. This Issue focusses on the treatment of metastatic and locally progressive patients. Patient selection, prognostication, diagnostics, innovative treatments, and new agents are discussed in this Issue. providing hope for those sarcoma patients who desperately need to balance cure and care.

Guest Editors

Prof. Dr. Michiel A. J. van de Sande

- Department of Pediatric Orthopedic Oncology, Prionces Maxima Center for pediatric Cancer, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands
- 2. Department of Orthopedic Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands

Prof. Dr. Rick Haas

Departments of Radiotherapy at the Netherlands Cancer Institute– Antoni van Leeuwenhoek Hospital and the Leiden University Medical Center, Leiden, The Netherlands

Deadline for manuscript submissions

closed (23 August 2021)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/58684

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

